Get the Stockscreener App
11.18
3.33%
0.36
Enanta Pharmaceuticals Inc stock is traded at $11.18, with a volume of 215.53K.
It is up +3.33% in the last 24 hours and up +8.23% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$10.82
Open:
$10.62
24h Volume:
215.53K
Relative Volume:
0.33
Market Cap:
$239.01M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-2.2586
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
+6.78%
1M Performance:
+8.23%
6M Performance:
+87.90%
1Y Performance:
+0.63%
1-Day Range:
$10.56
$11.25
1-Week Range:
$10.33
$11.45
52-Week Range:
$4.09
$15.34
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
11.18 | 312.19M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.43 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.39 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.27 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.73 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.48 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake - Yahoo Finance
What sentiment indicators say about Enanta Pharmaceuticals Inc. stockPortfolio Risk Report & Comprehensive Market Scan Insights - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What does recent volatility data suggest for Enanta Pharmaceuticals Inc.Options Play & Daily Profit Focused Stock Screening - newser.com
Is Enanta Pharmaceuticals Inc. stock ready for a breakoutQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
How Enanta Pharmaceuticals Inc. stock performs in rising dollar environmentRate Hike & Daily Growth Stock Investment Tips - newser.com
Why Enanta Pharmaceuticals Inc. stock is rated strong buyLayoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Enanta Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Portfolio Review & Precise Trade Entry Recommendations - newser.com
How Enanta Pharmaceuticals Inc. stock compares to growth peersMarket Volume Report & AI Enhanced Trading Alerts - newser.com
Using Ichimoku Cloud for Enanta Pharmaceuticals Inc. technicals2025 Geopolitical Influence & Weekly Top Performers Watchlists - newser.com
How Enanta Pharmaceuticals Inc. stock benefits from strong dollar2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Tools to assess Enanta Pharmaceuticals Inc.’s risk profileStock Surge & Free Technical Confirmation Trade Alerts - newser.com
Is Enanta Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Trade Ideas & Verified Entry Point Detection - newser.com
Trend analysis for Enanta Pharmaceuticals Inc. this weekJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
How to use a screener to detect Enanta Pharmaceuticals Inc. breakoutsPortfolio Profit Report & Free Community Consensus Stock Picks - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attentionQuarterly Market Summary & Weekly Chart Analysis and Guides - newser.com
How to forecast Enanta Pharmaceuticals Inc. trends using time seriesJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Will breakout in Enanta Pharmaceuticals Inc. lead to full recoveryJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Can Enanta Pharmaceuticals Inc. (9EP) stock deliver strong annual returnsTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Is Enanta Pharmaceuticals Inc. stock a good choice for value investorsStock Surge & Stock Portfolio Risk Control - newser.com
Will earnings trigger a reversal in Enanta Pharmaceuticals Inc.2025 Big Picture & Daily Stock Trend Watchlist - newser.com
How reliable is Enanta Pharmaceuticals Inc. (9EP) stock dividend growth2025 Analyst Calls & Technical Pattern Alert System - newser.com
What the charts say about Enanta Pharmaceuticals Inc. todayWeekly Profit Recap & Safe Entry Trade Reports - newser.com
What drives Enanta Pharmaceuticals Inc 9EP stock priceStraddle and Strangle Trades & Lower Drawdowns With Smart Position Sizing - earlytimes.in
How institutional buying supports Enanta Pharmaceuticals Inc. stockQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Can Enanta Pharmaceuticals Inc. stock resist market sell offsDip Buying & Safe Swing Trade Setups - newser.com
Is Enanta Pharmaceuticals Inc. stock attractive for retirement portfoliosDay Trade & Stepwise Swing Trade Plans - newser.com
How Enanta Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trade Review & Community Consensus Stock Picks - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30% - simplywall.st
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):